Molecular Templates to Participate in Upcoming Virtual Investor Conferences
02/26/2021 - 08:00 AM
AUSTIN, Texas, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, today announced that it will present and participate in 1-on-1 investor meetings at the Cowen 41st Annual Health Care Conference, the Barclays Global Healthcare Conference and the Oppenheimer 31st Annual Healthcare Conference.
Cowen 41st Annual Health Care Conference Conference Dates: March 1-4 Presentation Date and Time: Thursday, March 4th at 11:10 AM ET Barclays Global Healthcare Conference Conference Dates: March 9-11 Presentation Date and Time: Wednesday, March 10th at 3:00 PM ET
Oppenheimer 31st Annual Healthcare Conference Conference Dates: March 16-17 Presentation Date and Time: Wednesday, March 17th at 11:20 AM ET
Live webcasts of these presentations will be available in the “News and Events” section of the MTEM website at www.mtem.com . Additionally, replays of the webcasts will be available on the corporate website following the conferences.
About Molecular Templates Molecular Templates is a clinical-stage company focused on the discovery and development of targeted biologic therapeutics. Our proprietary drug platform technology, known as engineered toxin bodies, or ETBs, leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer and other serious diseases.
Investor Contact: Adam Cutler Chief Financial Officeradam.cutler@mtem.com 862-204-4006
Source: Molecular Templates, Inc.
MTEM Rankings
#3964 Ranked by Stock Gains
MTEM Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Austin
About MTEM
molecular templates (mtem) is a clinical-stage biopharmaceutical company targeting a variety of cancers through development of its innovative proprietary engineered toxin body (etb) platform. mtem’s first immunotoxin, mt-3724, is in clinical development for non-hodgkin’s lymphoma. pipeline products for additional oncology targets are being advanced toward clinical development. for more information, please visit mtem’s website at www.mtem.com.